Sentinel lymph node identification in early stage ovarian cancer: is it still possible after prior tumor resection?

Autor: Pim Laven, Roy Kruitwagen, Petra Zusterzeel, Brigitte Slangen, Toon van Gorp, Jochem van der Pol, Sandrina Lambrechts

Publikováno v: Journal of Ovarian Research, Vol 14, Iss 1, Pp 1-6 (2021)

Abstract Objective Sentinel lymph node (SLN) detection in ovarian cancer is feasible when tracers are injected before the pathological ovary is resected. This study aims to investigate whether the SLN identification is also feasible in patients whose

Externí odkaz: https://doaj.org/article/dba5934b4a604277a8307bac5aa7faeb

Feasibility of sentinel lymph node mapping of the ovary: a systematic review

Autor: Roy F.P.M. Kruitwagen, Martina Delle Marchette, Federica Dell'Orto, Pim Laven, Alessandro Buda, Sandrina Lambrechts

Publikováno v: International Journal of Gynecologic Cancer. 29:1209-1215

Pelvic and para-aortic lymphadenectomy is routinely performed in early ovarian cancer to define the stage of the disease. However, it may be associated with increased blood loss, operative time, and length of hospitalization. The sentinel lymph node

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::388301b8626fb18e5faaeebe1a4c592f
https://doi.org/10.1136/ijgc-2019-000606

Impact of CYP3A4*22 on Pazopanib Pharmacokinetics in Cancer Patients

Autor: Alwin D. R. Huitema, Paul Hamberg, Nielka P. van Erp, Hans Gelderblom, Stefan Sleijfer, Samira El Bouazzaoui, Carla M.L. van Herpen, Pim Laven, Ron H.N. van Schaik, Huixin Yu, Sander Bins, Neeltje Steeghs, Stijn L.W. Koolen, Ron H.J. Mathijssen

Publikováno v: Clinical Pharmacokinetics, 58, 651-658
Clinical Pharmacokinetics, 58(5), 651-658. Adis
Clinical Pharmacokinetics
Clinical Pharmacokinetics, 58(5), 651. Adis International Ltd
Clinical Pharmacokinetics, 58, 5, pp. 651-658
Clinical Pharmacokinetics, 58(5), 651-658. ADIS INT LTD

Background and Objective As pazopanib plasma trough concentrations are correlated with treatment outcome, we explored whether single nucleotide polymorphisms in the elimination pathway of pazopanib affect systemic pazopanib concentrations. Methods Th

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::be716526a797142d8209ef541e2aa207
https://doi.org/10.1007/s40262-018-0719-5